Howe & Rusling’s BioMarin Pharmaceuticals BMRN Stock Holding History

Howe & Rusling’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-40,764	Closed	-$2.88M	–	470
2025 Q1	$2.88M	Buy	40,764 +1,409	+4%	+$94.8K	0.24%	86
2024 Q4	$2.59M	Sell	39,355 -10,297	-21%	-$690K	0.22%	88
2024 Q3	$3.49M	Buy	49,652 +24,971	+101%	+$2.09M	0.3%	82
2024 Q2	$2.03M	Buy	24,681 +214	+0.9%	+$17.8K	0.19%	100
2024 Q1	$2.14M	Sell	24,467 -164	-0.7%	-$14.7K	0.2%	99
2023 Q4	$2.37M	Buy	24,631 +31	+0.1%	+$2.74K	0.25%	90
2023 Q3	$2.18M	Sell	24,600 -11,013	-31%	-$980K	0.26%	87
2023 Q2	$3.09M	Sell	35,613 -74	-0.2%	-$6.96K	0.35%	70
2023 Q1	$3.47M	Sell	35,687 -592	-2%	-$61.4K	0.41%	66
2022 Q4	$3.75M	Buy	36,279 +128	+0.4%	+$12K	0.47%	63
2022 Q3	$3.06M	Buy	36,151 +435	+1%	+$38.7K	0.41%	69
2022 Q2	$2.96M	Buy	35,716 +111	+0.3%	+$8.84K	0.38%	72
2022 Q1	$2.75M	Buy	35,605 +10,262	+40%	+$859K	0.32%	75
2021 Q4	$2.24M	Sell	25,343 -874	-3%	-$72.1K	0.26%	86
2021 Q3	$2.03M	Buy	+26,217	New	+$2.07M	0.25%	84
2021 Q1	–	Sell	-54	Closed	-$5K	–	949
2020 Q4	$5K	Sell	54 -135	-71%	-$10.7K	﹤0.01%	595
2020 Q3	$14K	Buy	189 +7	+4%	+$708	﹤0.01%	384
2020 Q2	$22K	Buy	182 +117	+180%	+$11.6K	﹤0.01%	335
2020 Q1	$5K	Hold	65	–	–	﹤0.01%	501
2019 Q4	$5K	Hold	65	–	–	﹤0.01%	546
2019 Q3	$4K	Hold	65	–	–	﹤0.01%	579
2019 Q2	$6K	Sell	65 -2	-3%	-$171	﹤0.01%	502
2019 Q1	$6K	Buy	67 +9	+16%	+$834	﹤0.01%	504
2018 Q4	$5K	Sell	58 -154	-73%	-$14.7K	﹤0.01%	536
2018 Q3	$21K	Buy	212 +120	+130%	+$12K	﹤0.01%	392
2018 Q2	$9K	Sell	92 -155	-63%	-$13.6K	﹤0.01%	468
2018 Q1	$20K	Buy	247 +149	+152%	+$12.8K	﹤0.01%	390
2017 Q4	$9K	Hold	98	–	–	﹤0.01%	477
2017 Q3	$9K	Buy	98 +15	+18%	+$1.32K	﹤0.01%	495
2017 Q2	$8K	Hold	83	–	–	﹤0.01%	522
2017 Q1	$7K	Hold	83	–	–	﹤0.01%	587
2016 Q4	$7K	Buy	83 +11	+15%	+$946	﹤0.01%	586
2016 Q3	$7K	Hold	72	–	–	﹤0.01%	584
2016 Q2	$6K	Hold	72	–	–	﹤0.01%	570
2016 Q1	$6K	Buy	72 +4	+6%	+$325	﹤0.01%	621
2015 Q4	$7K	Sell	68 -2	-3%	-$209	﹤0.01%	565
2015 Q3	$7K	Hold	70	–	–	﹤0.01%	563
2015 Q2	$10K	Hold	70	–	–	﹤0.01%	516
2015 Q1	$9K	Sell	70 -44	-39%	-$4.66K	﹤0.01%	498
2014 Q4	$10K	Hold	114	–	–	﹤0.01%	496
2014 Q3	$8K	Buy	+114	New	+$7.49K	﹤0.01%	519
2014 Q2	–	Sell	-81	Closed	-$6K	–	849
2014 Q1	$6K	Hold	81	–	–	﹤0.01%	630
2013 Q4	$6K	Hold	81	–	–	﹤0.01%	564
2013 Q3	$6K	Buy	81 +12	+17%	+$798	﹤0.01%	663
2013 Q2	$4K	Buy	+69	New	+$4.3K	﹤0.01%	731

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Howe & Rusling's BMRN Position: Q2 2025 in Review

Howe & Rusling sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 40,764 shares — an estimated $2.88M sold.

Howe & Rusling first reported a position in BMRN in Q2 2013 and held it in 45 quarters. The position peaked at $3.75M in Q4 2022. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

Howe & Rusling reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Howe & Rusling sold 40,764 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $2.88M.
Howe & Rusling first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 45 quarters.
Howe & Rusling's BioMarin Pharmaceuticals position peaked at $3.75M in Q4 2022.
582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Howe & Rusling's 13F filing for Q2 2025, filed 12 Aug 2025.